Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech ChartsFundamental Analysis of Neuland Laboratories - Growth / Value Index
NEULANDLAB - Valuation Highlights
Valuation Analysis
Tremendous increasing in Book Value last 3 year
Tsr Value Index - Poor Score of 27.78
Expensive - Price to Intrinsic Value of 2.77
Price to Earning Ratio is 100.53 and EV to EBITDA is 56.16 suggesting that it is very expensive
Price to Book Ratio of 12.43 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 105.22 | 59.54 | 120.28 % | ||
| Price to Book | 13.01 | 10.16 | 60.62 % | 12.16 | |
| Price to Sales | 13.93 | 10.49 | 101.50 % | ||
| Enterprise Value to EBITDA Multiple | 36.87 | 116.82 % |
NEULANDLAB - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Company Earning excess return
Good Return On Capital Employed of 15.66
Good Return on Equity of 12.36% is achieved by the company
Good Net Margin of 13.24% is achieved by the company
Tsr Profitability Index - Poor Score of 27.50
Very Low Dividend Yield of 0 %
EPS decline for last four quarters
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 12.36 | 17.06 | -27.08 % | 0.912 | |
| Return On Asset | 8.74 | 11.93 | -27.13 % | 0.638 | |
| Net Profit Margin | 13.24 | 17.61 | -8.52 % | 4.75 | |
| Operating Profit Margin | 60.11 | 16.89 | -32.31 % | 11.78 | |
| EBITDA Margin | 23.59 | 28.45 | -6.67 % | 14.47 |
Highlights
| Market Cap | 184340 M |
| Enterprise Value | 184405 M |
| Price/Book TTM | 13.01 |
| Outstanding Share | 12829.90 K |
| Float/ Outstanding Share | 56.05% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 7.52 |
| Peter Lynch Ratio | -0.127 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 19.13 |
| Sloan Ratio | 0.111 |
| Peter Lynch Fair Value | 3413.89 |
NEULANDLAB - Growth Highlights
Growth Analysis
Steady increase in Total Assets for last 3 Years
Quarterly sales in last 5 Quarter is trending down
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 1329.98 (Cr) | 5.24 % | 10.84 % |
| Gross Profit | 639.60 (Cr) | 42.97 % | 10.57 % |
| EBITDA | 313.74 (Cr) | 11.57 % | 27.66 % |
| Net Profit | 176.14 (Cr) | 13.32 % | 50.02 % |
| EPS | 136.56 | 13.32 % | NA |
NEULANDLAB - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 89.06
Altman Z Score of 18.37 suggests good Stability
Company financial liquidity has improved
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.091 | 35.21 % | 0.091 | |
| Cash Ratio | 0.556 | 103.51 % | ||
| Quick Ratio | 1.62 | 21.30 % | 1.62 | |
| Shareholders Equity | 69.95 | -0.065 % | ||
| Debt to EBITDA | 0.330 | 81.75 % |
Historical Valuation Ratios of Neuland Laboratories
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Neuland Laboratories
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Neuland Laboratories
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Neuland Laboratories
Historical Solvency Ratios
Loading ...